Femme et Homme
- | Pays :
- France
- Italy
- Australia
- Les 2 autres...
- | Organes : -
- | Spécialités : -
Extrait
BRF113710 is a Phase II, single-arm, open-label study to assess the efficacy, safety, and tolerability of GSK2118436 administered twice daily as a single agent in subjects with BRAF mutant metastatic melanoma. Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
Critère d'inclusion
- Melanoma